AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Viridian Therapeutics Inc... (VRDN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

19.46

0.25 (1.30%)

At close: Jan 29, 2025, 3:59 PM

19.43

-0.15%

After-hours Jan 29, 2025, 04:00 PM EST

undefined% (undefined)

Bid	17.17
Market Cap	1.54B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.32
PE Ratio (ttm)	-4.5
Forward PE	n/a
Analyst	Buy

Ask	20
Volume	677,961
Avg. Volume (20D)	1,394,446
Open	19.12
Previous Close	19.21
Day's Range	18.98 - 19.86
52-Week Range	11.40 - 27.20
Beta	undefined

About VRDN

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 18, 2014

Employees 94

Stock Exchange NASDAQ

Ticker Symbol VRDN

Website https://www.viridiantherapeutics.com

Analyst Forecast

According to 12 analyst ratings, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 74.72% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Viridian Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $48.77K, reflecting a -32.26% YoY shrinking and earnings per share of -1, making a -25.93% decrease YoY.

Why Price Moved

1 month ago

+20.67%

Viridian Therapeutics shares are trading higher af... Unlock content with Pro Subscription

4 months ago

+7.76%

Viridian Therapeutics shares are trading higher after BTIG raised its price target on the stock from $56 to $61.

News

1 month ago · seekingalpha.com

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing...

1 month ago · seekingalpha.com

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to T...

1 month ago · seekingalpha.com

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved th...

1 month ago · investors.com

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Therapeutics Skyrockets After Besting Amge...

1 month ago · reuters.com

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.

1 month ago · businesswire.com

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

1 month ago · businesswire.com

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

1 month ago · businesswire.com

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

2 months ago · zacks.com

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.